Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4536 Follow-up is not justified in patients with typical lung carcinoids treated with curative intent

Introduction: Typical carcinoids (TC) are well-differentiated neuroendocrine neoplasms of the lung with generally favourable prognosis. Recurrence is rare in TC patients treated with curative intent, yet current ENETS guidelines recommend extensive follow-up, including regular and long-term imaging.

Conference:

Presenting Author: Lau T

Authors: Lau T, Soldath P, Rewitz K, Jepsen P, Knigge U,

Keywords: typical carcinoid, lung nen, follow-up programme,

#4418 Endoscopic ultrasound-guided radiofrequency ablation is a safe and efficient treatment of symptomatic insulinomas – A single centre experience of 14 patients

Introduction: The vast majority of insulinomas are benign and less than 20 mm. Surgery is considered as standard treatment, but complications are significant. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) represents a novel and minimally invasive approach.

Conference:

Presenting Author: Andreassen M

Authors: Andreassen M, Kovacevic B, Brink L, Hansen C, Knigge U,

Keywords: Insulinoma, Benign, EUS, radiofrequency ablation,

#4412 25-years of experience with somatostatin receptor-based therapy in patients with small intestinal neuroendocrine tumours

Introduction: Small intestinal neuroendocrine tumours are well-differentiated and express type 2 somatostatin receptors (SSTR2). Treatment with somatostatin analogues (SSA) (octreotide or lanreotide) has been a cornerstone in controlling tumour growth for 25 years. Peptide Receptor Radionuclide Therapy (PRRT), utilising radiolabelled SSA, was introduced in our institution in May 2009 as primarily 2nd line treatment after progression on SSA. The standard PRRT regimen includes 4 cycles of PRRT (7.4 GBq 177Lu-DOTATATE every eight weeks). Re-treatment protocols remain debated.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Oturai P, Langer S, Møller S, Hansen C,

Keywords: SSA, PRRT, small intestinal NET,

#4248 Tryptophan pathway metabolites as prognostic biomarkers of recurrent disease in curatively operated neuroendocrine tumor patients

Introduction: The majority of NET patients experience recurrent disease after curative surgery. There is a need for prognostic biomarkers in this patient group.

Conference:

Presenting Author: Johansen S

Authors: Johansen S, Hansen T, Goll R, Florholmen J,

Keywords: Plasma Tryptophan Metabolites, Prognostic Biomarker, Recurrent Disease after Curative Surgery,

#3992 Recurrence free survival and disease-specific survival in patients with pancreatic neuroendocrine neoplasms: A single center retrospective study of 413 patients

Introduction: The prognosis and impact of different prognostic factors in pancreatic neuroendocrine neoplasms (pNEN) remains controversial.

Conference:

Presenting Author: Andreassen M

Authors: Møller S, Langer S, Slott C, Krogh J, Palnæs Hansen C,

Keywords: Pancreatic neuroendocrine neoplasms incidence, clinical presentation, prognosis,